Recently the University of Oxford signed a partnership with Apollo Therapeutics.

Apollo Therapeutics – a biopharmaceutical portfolio company – will work closely with the University of Oxford to help its academics translate their research into novel, first-in-class therapeutics for patients. The collaboration aims to de-risk and accelerate the development of academic research ideas along the translation pathway. The range of therapeutics Apollo are interested in is fairly broad, spanning small molecules, biologics and vaccines. Additionally, the stage at which Apollo seek to engage with research is similarly broad, and encompasses early target discovery and validation through to clinical trials. The company are disease agnostic.

Come along if you’re interested to learn more about Apollo Therapeutics or interested in collaborating with them.